Relation of plasma homocysteine to plasma amyloid beta levels

Neurochemical Research

Volumn 32, Issue 4-5, 2007, Pages 775-781

  Luchsinger, José A ^a,b   Tang, Ming Xin ^a,c   Miller, Joshua ^d   Green, Ralph ^d   Mehta, Pankash D ^f   Mayeux, Richard ^a,b,c,e  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b Columbia University College of Physicians and Surgeons ^*  (United States)

^c University of California ^*  (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

^f NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

Alzheimer's disease; Amyloid beta; Homocysteine; Plasma

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; BIOLOGICAL MARKER; CREATININE; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE;

AGE DISTRIBUTION; AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE MARKER; ETHNIC DIFFERENCE; FEMALE; HUMAN; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; SEX DIFFERENCE;

AGED; AMYLOID BETA-PROTEIN; ANALYSIS OF VARIANCE; APOLIPOPROTEIN E4; BIOLOGICAL MARKERS; COGNITION DISORDERS; CREATININE; CROSS-SECTIONAL STUDIES; DEMENTIA; FEMALE; HOMOCYSTEINE; HUMANS; LINEAR MODELS; MALE; MEDICARE; NEW YORK CITY; PEPTIDE FRAGMENTS;

EID: 33947573975     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11064-006-9207-7     Document Type: Article

References (48)

1. Seshadri S, Beiser A, Selhub J et al (2002) Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 346:476-483
2. Luchsinger JA, Tang M-X, Shea S, Miller J, Green R, Mayeux R (2004) Plasma homocysteine levels and risk of Alzheimer disease. Neurology 62:1972-1976
3. Budge MM, de Jager C, Hogervorst E, Smith AD, Oxford Project To Investigate Memory and Ageing (2002) Total plasma homocysteine, age, systolic blood pressure, and cognitive performance in older people. J Am Geriatr Soc 50:2014-2018
4. Miller JW, Green R, Mungas DM, Reed BR, Jagust WJ (2002) Homocysteine, vitamin B6, and vascular disease in AD patients. Neurology.58:1471-1475
5. Seshadri S, Wolf PA (2003) Homocysteine and the brain: vascular risk factor or neurotoxin? Lancet Neurol 2:11
6. Ritchie K, Lovestone S (2002) The dementias. Lancet 360:1759-1766
7. Petersen RC, Doody R, Kurz A et al (2001) Current concepts in mild cognitive impairment. Arch Neurol 58:1985-1992
8. Cummings JL (2004) Alzheimer's disease. N Engl J Med 351:56-67
9. Selkoe DJ (2000) The origins of Alzheimer disease: a is for amyloid. JAMA 283:1615-1617
10. Frank RA, Galasko D, Hampel H et al (2003) Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiol Aging 24:521-536
11. Schupf N, Patel B, Silverman W et al (2001) Elevated plasma amyloid beta-peptide 1-42 and onset of dementia in adults with Down syndrome. Neurosci Lett 301:199-203
12. Scheuner D, Eckman C, Jensen M et al (1996) Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 2:864-870
13. Mayeux R, Tang MX, Jacobs DM et al (1999) Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease. Ann Neurol 46:412-416
14. Mayeux R, Honig LS, Tang M-X et al (2003) Plasma A{beta}40 and A{beta}42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology 61:1185-1190
15. Assini A, Cammarata S, Vitali A et al (2004) Plasma levels of amyloid {beta}-protein 42 are increased in women with mild cognitive impairment. Neurology 63:828-831
16. Tang MX, Stern Y, Marder K et al (1998) The APOE-epsilon4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. JAMA 279:751-755
17. Stern Y, Andrews H, Pittman J et al (1992) Diagnosis of dementia in a heterogeneous population. development of a neuropsychological paradigm-based diagnosis of dementia and quantified correction for the effects of education. Arch Neurol 49:453-460
18. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) (1994) American Psychiatric Association, Washington, DC, pp 143-147
19. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL (1982) A new clinical scale for the staging of dementia. Br J Psychiatry 140:566-572
20. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 34:939-944
21. Honig LS, Tang MX, Albert S et al (2003) Stroke and the risk of Alzheimer disease. Arch Neurol 60:1707-1712
22. Mayeux R, Honig LS, Tang MX et al (2003) Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology 61:1185-1190
23. Luchsinger JA, Tang MX, Shea S, Miller J, Green R, Mayeux R (2004) Plasma homocysteine levels and risk of Alzheimer disease. Neurology 62:1972-1976
24. Gilfix BM, Blank DW, Rosenblatt DS (1997) Novel reductant for determination of total plasma homocysteine. Clin Chem 43:687-688
25. Fleiss JL (1981) Statistical methods for rates and proportions, 2nd edn. Joseph Wiley and Sons
26. Hofman A, Ott A, Breteler MM et al (1997) Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam study. Lancet 349:151-154
27. Luchsinger J, Mayeux R (2004) Cardiovascular risk factors and Alzheimer's disease. Curr Atheroscler Rep 6:261-266
28. Aisen PS, Egelko S, Andrews H et al (2003) A pilot study of vitamins to lower plasma homocysteine levels in Alzheimer disease. Am J Geriatr Psychiatry 11:246-249
29. McIlroy SP, Dynan KB, Lawson JT, Patterson CC, Passmore AP (2002) Moderately elevated plasma homocysteine, methylenetetrahydrofolate reductase genotype, and risk for stroke, vascular dementia, and Alzheimer disease in Northern Ireland. Stroke 33:2351-2356
30. McCaddon A, Hudson P, Davies G, Hughes A, Williams JH, Wilkinson C (2001) Homocysteine and cognitive decline in healthy elderly. Dement Geriatr Cogn Disord 12:309-313
31. Prins ND, Den Heijer T, Hofman A et al (2002) Homocysteine and cognitive function in the elderly: the Rotterdam scan study. Neurology 59:1375-1380
32. Sachdev PS, Valenzuela MJ, Brodaty H et al (2003) Homocysteine as a risk factor for cognitive impairment in stroke patients. Dement Geriatr Cogn Disord 15:155-162
33. den Heijer T, Vermeer SE, Clarke R et al (2003) Homocysteine and brain atrophy on MRI of non-demented elderly. Brain 126:170-175
34. Bostom AG, Rosenberg IH, Silbershatz H et al (1999) Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: the Framingham study. Ann Intern Med 131:352-355
35. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG (1995) Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 346:1395-1398
36. Vermeer SE, van Dijk EJ, Koudstaal PJ et al (2002) Homocysteine, silent brain infarcts, and white matter lesions: the Rotterdam scan study. Ann Neurol 51:285-289
37. Honig LS, Tang MX, Albert S et al (2003) Stroke and the risk of Alzheimer disease. Arch Neurol 60:1707-1712
38. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM (2003) Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 348:1215-1222
39. He K, Merchant A, Rimm EB et al (2004) Folate, vitamin B6, and B12 intakes in relation to risk of stroke among men. Stroke 35:169-174
40. Toole JF, Malinow MR, Chambless LE et al (2004) Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: The Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 291:565-575
41. Ho PI, Collins SC, Dhitavat S et al (2001) Homocysteine potentiates beta-amyloid neurotoxicity: role of oxidative stress. J Neurochem 78:249-253
42. Mok SS, Turner BJ, Beyreuther K, Masters CL, Barrow CJ, Small DH (2002) Toxicity of substrate-bound amyloid peptides on vascular smooth muscle cells is enhanced by homocysteine. Eur J Biochem 269:3014-3022
43. Kruman II, Culmsee C, Chan SL et al (2000) Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J Neurosci 20:6920-6926
44. Kruman II, Kumaravel TS, Lohani A et al (2002) Folic acid deficiency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of Alzheimer's disease. J Neurosci 22:1752-1762
45. Selkoe DJ (1997) Alzheimer's disease: genotypes, phenotypes, and treatments. Science 275:630-631
46. Pak KJ, Chan SL, Mattson MP (2003) Homocysteine and folate deficiency sensitize oligodendrocytes to the cell death-promoting effects of a presenilin-1 mutation and amyloid beta-peptide. Neuromol Med 3:119-128
47. Pacheco-Quinto J, Rodriguez de Turco EB, DeRosa S et al (2006) Hyperhomocysteinemic Alzheimer's mouse model of amyloidosis shows increased brain amyloid [beta] peptide levels. Neurobiol Dis 22:651-656
48. Irizarry MC, Gurol ME, Raju S et al (2005) Association of homocysteine with plasma amyloid {beta} protein in aging and neurodegenerative disease. Neurology 65:1402-1408